Biopharma · FDA Approvals · Stock
PTHS Pelthos Therapeutics
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commer…
Assets on file: abametapir, D-Fi
Catalyst calendar
Dated catalysts for PTHS, including recently decided ones.
Nothing scheduled in this window.
Recent first-hand events
Every first-hand event for PTHS, newest first.
PTHSPelthos TherapeuticsPelthos to Merge with Castle Creek Biosciences, Adding D-Fi for DEB
Pelthos Therapeutics agreed to merge with Castle Creek Biosciences, acquiring the late-stage D-Fi (dabocemagene autoficel; FCX-007) program which has Orphan Drug Designation for dystrophic epidermolysis bullosa. The deal includes up to 5.8 million additional shares upon FDA approval of D-Fi plus up to $300 million in milestones. The transaction is expected to close by end of Q1 2027.
PTHSPelthos TherapeuticsPelthos acquires Xeglyze (abametapir) for head lice
Pelthos acquired worldwide rights to the already FDA-approved Xeglyze (abametapir) from Hatchtech for $1.8 million with no future payments. The company plans to relaunch the product in the first half of 2027, adding a second commercial asset to its portfolio alongside ZELSUVMI.
Peers by market cap
Companies in the same sector closest to PTHS in market value.
VERUVeruMarket cap $37.3M
NNVCNanoViricidesMarket cap $33.9M
ALDXAldeyraMarket cap $33.8M · 2 tracked drugsIIRLAIRulya TherapeuticsMarket cap $33.5M
UGUnited-GuardianMarket cap $32.5M · 1 tracked drug
QNCXQuince TherapeuticsMarket cap $32.3M · 2 tracked drugs · 2 upcoming catalysts
ACETAdicet BioMarket cap $32.0M · 2 tracked drugs · 1 upcoming catalyst
INMBINmune BioMarket cap $40.2M · 2 tracked drugs